C S Pramesh: Welcome move to exempt some important cancer medicines from customs duty

C S Pramesh, Director of the Tata Memorial Hospital and the Professor and Head of Thoracic Surgery at the Tata Memorial Centre, shared on X:

“Welcome move to exempt some important cancer medicines from customs duty. Trastuzumab Deruxtecan, Osimertinib and Durvalumab all improve outcomes in breast, lung and some other common cancers, and this will make these drugs more affordable for patients with these cancers.

The pharmaceutical industry should ensure that this benefit is passed on to patients requiring these drugs. Also, I would urge the government to continue to reduce or exempt taxes on lifesaving drugs to make healthcare more affordable for our patients.”

Source: C S Pramesh/X